Tielsch James M, Khatry Subarna K, Stoltzfus Rebecca J, Katz Joanne, LeClerq Steven C, Adhikari Ramesh, Mullany Luke C, Black Robert, Shresta Shardaram
Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205-2013, USA.
Lancet. 2007 Oct 6;370(9594):1230-9. doi: 10.1016/S0140-6736(07)61539-6.
Zinc supplementation can reduce subsequent morbidity in children recovering from diarrhoea and respiratory illness in developing countries. However, whether routine supplementation would decrease morbidity and mortality in populations with zinc deficiency is unclear. We assessed the effect of daily zinc supplementation on children in southern Nepal.
We did a community-based, cluster-randomised, double-masked, placebo-controlled, 2x2 factorial trial in children aged 1-35 months. Treatment groups were placebo, iron and folic acid, zinc, and iron and folic acid with zinc, with daily doses of 12.5 mg iron, 50 microg folic acid, and 10 mg zinc. Study staff gave children tablets on 2 days each week and left tablets with caregivers for other days. All children received vitamin A supplementation twice per year. Results of the iron arm of the trial have been reported previously. Between October, 2001, and January, 2006, 41,276 children were enrolled into the placebo (n=20,308) or zinc (n=20,968) groups and were followed-up for 60,636.3 person-years. The primary outcome was child mortality, and analyses were by intention to treat. Daily reports of signs and symptoms of common morbidities in stratified random subsamples of children were assessed every week for 12 months. This study is registered at ClinicalTrials.gov, number NCT00109551.
2505 children refused to continue the trial and 3219 children were lost to follow-up. There was no significant difference in mortality between the zinc and placebo groups (316 vs 333 deaths; hazard ratio 0.92, 95% CI 0.75-1.12). Zinc had no effect on mortality in children younger than 12 months (181 vs 168 deaths; 1.04, 0.83-1.31); mortality was lower, but not statistically significantly so, in older children receiving zinc (135 vs 165; 0.80, 0.60-1.06). The frequency and duration of diarrhoea, persistent diarrhoea, dysentery, and acute lower respiratory infections did not differ between the groups.
Total mortality of children receiving zinc supplementation was not significantly different from that of children receiving placebo. Further data are needed from other populations with endemic zinc deficiency to confirm the potential age-specific effects reported in this study.
在发展中国家,补充锌可降低腹泻和呼吸道疾病康复期儿童后续发病的几率。然而,常规补充锌是否会降低锌缺乏人群的发病率和死亡率尚不清楚。我们评估了每日补充锌对尼泊尔南部儿童的影响。
我们在1至35个月大的儿童中开展了一项基于社区的整群随机、双盲、安慰剂对照的2×2析因试验。治疗组分别为安慰剂组、铁和叶酸组、锌组以及铁和叶酸加锌组,每日剂量分别为12.5毫克铁、50微克叶酸和10毫克锌。研究人员每周给儿童服药2天,其他日子则将药片留给照料者。所有儿童每年接受两次维生素A补充剂。该试验中铁剂组的结果此前已报告。在2001年10月至2006年1月期间,41276名儿童被纳入安慰剂组(n = 20308)或锌组(n = 20968),并随访了60636.3人年。主要结局指标是儿童死亡率,分析采用意向性分析。对分层随机抽取的儿童子样本中常见疾病体征和症状的每日报告进行为期12个月的每周评估。本研究已在ClinicalTrials.gov注册,注册号为NCT00109551。
2505名儿童拒绝继续试验,3219名儿童失访。锌组和安慰剂组的死亡率无显著差异(316例死亡对333例死亡;风险比0.92,95%置信区间0.75 - 1.12)。锌对12个月以下儿童的死亡率无影响(181例死亡对168例死亡;1.04,0.83 - 1.31);接受锌补充剂的大龄儿童死亡率较低,但无统计学意义(135例死亡对165例死亡;0.80,0.60 - 1.06)。两组之间腹泻、持续性腹泻、痢疾和急性下呼吸道感染的频率和持续时间无差异。
补充锌的儿童总死亡率与接受安慰剂的儿童无显著差异。需要来自其他锌缺乏流行地区的更多数据来证实本研究报告的潜在年龄特异性效应。